NanoString Technologies, a privately held provider of life science tools for translational research and developer of molecular diagnostics, has raised $20 million in a series D round of venture capital financing. The investment was made by new investors including GE, BioMed Ventures and Henri Termeer, former chairman and CEO of Genzyme Corp.
Existing venture investors, including Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners also took part in the equity financing. The company intends to use the funding to continue expanding NanoString’s life science tools business, as well as advance development of its first molecular diagnostic product, a breast cancer assay based on the PAM50 gene expression signature.
Click here for the release from Business Wire.